Regulation of prostatic smooth muscle contractility by intracellular second messengers: Implications for the conservative treatment of benign prostatic hyperplasia

Urologia Internationalis

Volumn 54, Issue 1, 1995, Pages 6-21

  Eckert, R E ^a   Schreier, U ^b   Drescher, P ^b   Madsen, P O ^b   Derouet, H ^a   Becht, E ^a   Steffens, J ^a   Ziegler, M ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Benign prostatic hyperplasia; Second messengers Ca^{2+< sup>; Smooth muscle; 1< inf> Adrenoccptors}

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; DIACYLGLYCEROL; INOSITOL 1,4,5 TRISPHOSPHATE; LOW MOLECULAR WEIGHT HEPARIN; NORADRENALIN; PERTUSSIS TOXIN; PHENYLEPHRINE; PHOSPHOLIPASE C; PROTEIN KINASE C; RYANODINE; THAPSIGARGIN;

ADRENERGIC TRANSMISSION; ARTICLE; CALCIUM CELL LEVEL; CONSERVATIVE TREATMENT; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PATCH CLAMP; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SECOND MESSENGER; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE FIBER; SMOOTH MUSCLE TONE;

CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEINS; HUMAN; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NOREPINEPHRINE; PHENYLEPHRINE; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROTEIN BINDING; RECEPTORS, ADRENERGIC, ALPHA-1; SECOND MESSENGER SYSTEMS; SUPPORT, NON-U.S. GOV'T;

EID: 0028926509     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000282685     Document Type: Article

References (45)

1. Walsh PC: Benign prostalic hyperplasia; in Walsh PC. Pcrlmuttcr AD, Slamey TA (eds): Campell's Urology. Philadelphia, Saunders, 1992, p 1099.
2. Gup DI, Shapiro E, Baumann M, Lcpor H: The contractile properties of human prostate adenomas: Insight into the development of infravcsical obstruction. Prostate 1989; 15:105.
3. Lcpor H: The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia. J Androl 1991; 12:6.
4. Caine M, Raz S, Ziegler M: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975, 47:193.
5. Drescher P, Eckert R. Madsen PO: Role of intracellular Ca2+-stores in prostatic smooth muscle contractions. Urol Res 1993:21:319.
6. Drescher P, Eckert R, Madsen PO: G-proteins in alpha I-adrenoceptor mediated prostatic smooth muscle contractions. Urol Res 1994;in press.
7. Drescher P, Eckert R. Madsen PO: Smooth muscle contractility in prostatic hyperplasia: Role of cyclic adenosine monophosphate. Prostate 1994:25:76.
8. Drescher P, Eckert R, Sparwasser C, Madsen PO: Alpha-1 receptor mediated smooth muscle regulation in benign prostatic hyperplasia. Scand J Urol Nephrol 1994; 157:33.
9. Lcpor H. Shapiro E: Characterization of the alphai-adrenergic receptor in human benign prostatic tissue. J Urol 1984:132:1226.
10. van Breemen C. Saida K: Cellular mechanisms regulating [Ca2+], in smooth muscle. Annu Rev Physiol 1989:51:315.
11. Walsh MP: Calcium regulation of smooth muscle contraction; in Marne D (ed): Calcium and Cell Physiology. Berlin, Springer, 1985, p 123.
12. Kamm KE, Stull JT: Regulation of smooth muscle contractile elements by second messengers. Annu Rev Physiol 1989;51:299.
13. Berridge MJ, Irvine R: Inositol trisphosphate. a novel second messenger in cellular cell signal transduction. Nature 1984;312:315-321.
14. Berridge MJ: Inositol trisphosphate and diacylglvcerol: Two interacting second messengers. Annu Rev Biochem 1987;56:159-193.
15. Bian J, Gosh TK, Wang JC, Gill DL: Identification of intracellular calcium pools: Selective modification by thapsigargin. J Biol Chem 1991;266:8801-8806.
16. Eckert R, Utz J, Mentzer RM, Trautwein W: Involvement of IP j induced Ca2+-release mechanisms in the adenosine induced cardiac Ca2+- current inhibition. Surgery 1993, 144:334-342.
17. Eckert R. Utz J, Trautwein W: Role of intracellular Ca2+-stores in the 5-HT induced Ca2+-current inhibition in neuroblastoma × glioma hybrid cells. Neuroscience 1993;153:25-28.
18. Foskett JK. Wong D: Free cytoplasmic Ca2+ concentration oscillations in thapsigargin treated parotid acinar cells arc caffeine sensitive and ryanodine sensitive. J Biol Chem 1991:266:14535.
19. Hamill OP, Marty A, Neher E, Sakmann FJ: Improved patch-clamp techniques for high resolution current recordings from cells and cellfree membrane patches. Pflügers Arch 1981: 391:85.
20. Neher E: Combined fura-2 and patch-clamp measurements in rat peritoneal mast cells; in Sellin LC, Libclius R, Thesleff S (eds): Neuromuscular Junction. 1987, pp 65-76.
21. Grynkicwicz G. Poenie M, Tsien RY: A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985:260:3440-3450.
22. Tsien RY, Rink TJ. Poenie M: Measurement of cytosolic free Ca2+ in individual small cells using fluorescence microscopy with dual excitation wavelength. Cell Calcium 1985;6:145- 157.
23. Derouet H. Eckert R. Trautwein W. Ziegler M: Muscular cavernous single cell analysis in patients with venoocclusivc disease. Eur Urol 1994;25:145-150.
24. Eckert R. Derouet H. Trautwein W. Ziegler M: On the mechanism of PGEl induced Ca2+-current inhibition of cavernous smooth muscle myocytes in patients with venoocclusive disease. Invest Urol 1993;in press.
25. Eckert RE, Zaubitzer T. Derouet H, Ziegler M: Intracellular control of cavernous smooth muscle contractility. J Urol 1994;151:814.
26. Eckert R, Trautwein W: Inhibitory modulation of fast and slow Ca2+-currents in neuroblastoma × glioma hybrid cells during differentiation. Neurosci Lett 1991:119:123-126.
27. Eckert R, Utz J, Trautwein W: Downregulation of Cardiac L-Type Ca2+-Currents by Adenosine. Tokyo, Springer. 1994.
28. Eckert RE. Schrcier U, Drescher P, Madsen PO. Ziegler M: Intracellular pathways regulating the cytoplasmic Ca2+-concentration in prostatic smooth muscle cells. J Urol 1994:151: 276.
29. Cambridge D, Davcy MJ, Massingham R: Prazosin, a selective antagonist of postsynaptic α-adrenoceptors. Br J Pharmacol 1977:59:514.
30. Honda K, Nakagawa C, Terai M: Further studies on ± YM 617, a potent and selective α-l adrenoceptor antagonist and its individual optical enantiomers. Naunvn Schmiedcbergs Arch Pharmacol 1987:336:295.
31. Hisayama T. Takayanagi I: Ryanodine: Its possible mechanism of action in the caficine-sensitive calcium store of smooth muscle. Pflügers Arch 1988:412:376.
32. line M. Kobayashi T, Endo M: Use of ryanodine for functional removal of the calcium store in smooth muscle cells of the guinea-pig. Biochem Biophys Res Commun 1988:152: 417.
33. Shirna H. Blaustcin MP: Modulation of evoked contractions in rat arteries by ryanodine, thapsigargin and cyclopiazonic acid. Circ Res 1992: 70:969.
34. Mignery GA, Südhof TC. Takci K, De Camili P: Putative receptor for inositol trisphosphate similar to ryanodine receptor. Nature 1989; 342:192-195.
35. Nosck TM. Williams MF, Zeigler ST. Godt RE: Inositol trisphosphate enhances calcium release in skinned cardiac and skeletal muscle. Am J Physiol 1986;250:C807-C811.
36. Tastrup O: Role of Ca-ATPases in regulation of cellular Ca2+ signalling, as studied with the selective microsomal Ca2+ ATPase inhibitor, thapsigargin. Agents Actions 1990:29:8.
37. Brown A. Birnbaumer L: Ionic channels and their regulation by G-protein subunits. Annu Rev Physiol 1990;52:197.
38. Cockroft S: Phosphoinositide phosphodiesterase: Regulation by a novel guanine nucleotide binding protein, Gp. Trends Pharmacol Sci 1987;12:75.
39. Gilman AG: G-proteins: Transducers of reccptor-gencrated signals. Annu Rev Biochem 1987:56:615.
40. Rosenthal W, Hescheler J. Eckert R. Offermanns S, Schmidt A, Hinsch KD. Spicher K, Trautwein W. Schultz G: Pertussis toxin-sensitive G-proteins: Participation in the modulation of voltage-dependent Ca2+ channels by hormones and neurotransmitters; in Nishizuka (ed): Advances in Second Messenger and Phosphoprotein Research. New York. Raven Press, 1990 pp 89-95.
41. Ui M: Islet-activation protein, pertussis toxin: A probe for functions of the inhibitory guanine nucleotide regulatory component of adenylate cyclase. Trends Pharmacol Sci 1984;5:277.
42. lgnarro LJ, Kadowitz P: The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Annu Rev Pharmacol Toxicol 1985;25:171-191.
43. Lincoln TM: Cyclic GMP and mechanisms of vasodilatation. Pharmacol Ther 1989:41:479- 502.
44. Soralyo AV, Bond M, Somlyo AP, Scarpa A: Inositol trisphosphate induced Ca release and contraction in vascular smooth muscle. Proc Natl Acad Sci USA 1985:82:5231.
45. Han CH. Abel PW, Minncman KP: Alpha-1 adrenoceptor subtypes linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle. Nature 1987;329:333.